En Es
Categories

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) is a biotechnology company specializing in clinical laboratory instruments and in vitro diagnostic reagents. The company offers a range of fully automated, integrated CLIA analyzers and matching reagent kits covering more than 100 parameters. SNIBE also supplie ...
Gold member
Products Covid-19NewsSummaryEvents
Close

Covid-19 Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Clinical Laboratory

SARS-CoV-2 RT-PCR Assay
Molecision SARS-CoV-2 RT-PCR Assay (Lyophilized)

The Molecision SARS-CoV-2 RT-PCR Assay (Lyophilized) is a one-step, lypholized and easy transporting RT-PCR assay for SARS-CoV-2 detection from nasopharyngeal swabs, oropharyngeal swabs and sputum. The high sensitivity and high specificity assay delivers results around 60 minutes after extraction and has a sensitive LOD of 250 copies/mL.
More details

SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Professional use)

The RapiSafe SARS-CoV-2 Antigen Rapid Test (Professional use) is intended for early detection of SARS-CoV-2 specific antigen from suspected COVID-19 cases. It quickly identifies potentially contagious patients by delivering test results in 15 minutes with outstanding test specificity and sensitivity irrespective of the SARS-CoV-2 variants.
More details

SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Colloidal Gold)

The RapiSafe SARS-CoV-2 Antigen Rapid Test (Colloidal Gold) is designed for early detection of SARS-CoV-2 specific antigen from suspected COVID-19 cases. Faster and more convenient than PCR test, it does not require any special/additional instruments and delivers test results in 15 minutes.
More details

SARS-CoV-2 S-RBD IgG Serology Test
MAGLUMI SARS-CoV-2 S-RBD IgG

MAGLUMI SARS-CoV-2 S-RBD IgG is a fully automated quantitative serology test to detect IgG antibodies against S-RBD (the receptor-binding domain of S protein). S-RBD binding antibodies have a strong correlation to the level of neutralizing antibodies, indicating its medical value of measuring immunity in natural infection and vaccination. The CE mark test has 99.6% specificity and 100% sensitivity at 15 days post-onset of symptom for COVID-19, which can provide more accurate and reasonable results within 30 minutes with ONLY 10uL sample volume. The test can be run on a global installed base of 16,000 MAGLUMI CLIA systems, including MAGLUMI X8 immunoassay analyzer, which can run up to 14,400 tests per day. Multiple MAGLUMI X8 could be connected to form a modular system to meet the high demands of large hospitals, especially during the COVID-19 pandemic period.
More details

CLIA Analyzer
MAGLUMI X8

MAGLUMI X8 is the latest and powerful CLIA analyzer with a super high throughput of up to 600 tests per hour to address high testing needs and improve laboratory efficiency. It offers continuous loading of samples and reagents, along with onboard capability of up to 300 samples and 42 reagents. MAGLUMI X8 is capable of being linked to a Laboratory Automation System (TLA).
More details

SARS-CoV-2 Neutralizing Antibody Assay
MAGLUMI SARS-CoV-2 Neutralizing Antibody Assay

The fully automatic MAGLUMI SARS-CoV-2 Neutralizing Antibody Assay aims to detect neutralizing antibodies against the SARS-CoV-2, which indicate the immune status of the vaccine receivers and the COVID-19 patients. Different from the traditional neutralizing antibody detection method-the plaque reduction neutralization test (PRNT) which requires BSL-3 laboratories and may take up to five days to complete, the assay is capable of providing the first result within 20 minutes when combined with MAGLUMI CLIA analyzers.
More details

SARS-CoV-2 & Flu A/B RT-PCR Assay
Molecision SARS-CoV-2 & Flu A/B RT-PCR Assay

The Molecision SARS-CoV-2 & Flu A/B RT-PCR Assay meets the need for the screening of SARS-CoV-2, Influenza A and Influenza B in one single tube. It uses nasopharyngeal swabs, oropharyngeal swabs and nasopharyngeal/nasal wash to provide results around 1.5 hours after extraction.
More details

SARS-CoV-2, Flu & RSV RT-PCR Assay
Molecision SARS-CoV-2, Flu & RSV RT-PCR Assay

The Molecision SARS-CoV-2, Flu & RSV RT-PCR Assay is intended for the identification of SARS-CoV-2, Flu and RSV from a single respiratory sample. It uses nasopharyngeal swabs, oropharyngeal swabs and nasopharyngeal/nasal wash to provide results around 1.5 hours after extraction.
More details

SARS-CoV-2 Ag (CLIA) Kit
Maglumi SARS-CoV-2 Ag (CLIA) Kit

The Maglumi SARS-CoV-2 Ag (CLIA) Kit with CE mark is a chemiluminescence immunoassay solution for the quantitative detection of nucleocapsid antigens of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples taken from suspected COVID-19 patients. The assay has demonstrated 97.7% sensitivity and 99.6% specificity, and could aid in the early detection of SARS-CoV-2 virus from suspected COVID-19 cases
More details

SARS-CoV-2 Test
Molecision SARS-CoV-2 RT-PCR Assay

The Molecision SARS-CoV-2 RT-PCR Assay is a real time reverse transcriptase (RT) polymerase chain reaction (PCR) used for the qualitative detection of SARS-CoV-2 from nasal, oropharyngeal, nasopharyngeal swabs and BALF (bronchoalveolar lavage fluid) of suspected cases of COVID-19. The dual target assay with three target primers for detecting ORF1ab and N genes is also available as a CE-IVD test for countries accepting the CE-mark.
More details

SARS-CoV-2 Antibody Test
MAGLUMI SARS-CoV-2 S-RBD IgG

The MAGLUMI SARS-CoV-2 S-RBD IgG is designed for the quantitative detection of antibodies to the receptor-binding domain of the S protein and has 99.6% specificity and 100% sensitivity at 15 days post-onset of symptom for COVID-19, which can provide more accurate and reasonable results. The test can be run on MAGLUMI CLIA systems, including the MAGLUMI X8 immunoassay analyzer, and provides results within 30 minutes using only 10uL sample volume.
More details

SARS-CoV2 Antibody Test
MAGLUMI 2019-nCoV (SARS-CoV-2) IgM/IgG kits

The MAGLUMI 2019-nCoV (SARS-CoV-2) IgM/IgG kits are the world's first CE Marked CLIA antibody assay for COVID-19 and offer a joint detection solution (IgG+IgM) for SARS-CoV-2 to ensure high clinical sensitivity. As the world's fastest fully automated CLIA solution (high throughput and sensitivity method), the kits enable antibody detection with numerical results using only 10μL sample volume and offers rapid detection within 30 minutes (analyzer model dependent).
More details
Close

News of Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Snibe Diagnostic exhibe analizadores en MEDLAB Europa 2018

10 Oct 2018
Snibe Diagnostic exhibe analizadores en MEDLAB Europa 2018
 Shenzhen New Industries Biomedical Engineering Co., Ltd. [(Snibe Co. Ltd.) Shenzhen, China] mostró su última gama de analizadores de inmunoensayo quimioluminiscentes en MEDLAB Europa 2018, celebrada en Barcelona, España, del 2 al 4 de octubre de 2018. Más de 150 expositores exhibieron las últimas tecnologías de vanguardia y los últimos desarrollos en la industria de los laboratorios médicos en la segunda edición de la exhibición. MEDLAB Europa 2018 le dio la bienvenida a más de 2.600 visitantes y delegados internacionales, ofreciendo a los fabricantes internacionales la oportunidad de establecer contactos con más de 1.000 distribuidores y comercializadores médicos de España, Italia, Francia, Alemania, Portugal y otros países.

Read More

SNIBE Exhibited at 2014 AACC Annual Meeting & Clinical Expo

30 Aug 2014
On July 29 to July 31, SNIBE attended the 2014 AACC Annual meeting & Clinical Expo, with its 72 square meters booth, which is a new record in SNIBE’s history. The 2014 AACC was held in Chicago, Illinois, the Great Lakes region, with more than 700 exhibitors and 2,000 booths. SNIBE attended this global event which strongly influences north and Latin American with its newest booth design. SNIBE focused on showcasing the newest model of MAGLUMI CLIA family, MAGLUMI 800, which will come into the market at the end of this year. MAGLUMI 800 attracted all the new and old customers’ attentions. Most of them came forward to ask the details of MAGLUMI800 carefully. In addition to the agents and end-customers, the local US laboratories also had a deep impression on our comprehensive reagents menu and diverse analyzers and said they are looking forward to our MAGLUMI series. For our FDA certificate is well underway, we believe that before long we will enter the world's largest diagnostics market to service US customers. Not only customers, the peer companies’ visit to our booth also reflected that the influence of SNIBE was enhanced. For example, the stuff from ABBOTT, whose headquarter is situated in Illinois, came to our booth to learn about our products and technologies, and discuss the possibilities of potential cooperation relationship. 2015, see you in Atlanta.

SNIBE has participated in the 69th CMEF (Shenzhen)

06 May 2013
The 69th China International Medical Equipment Fair (CMEF) was held in Shenzhen from 17th-20th April 2013, which has experienced 34 years. Due to its continuous innovation, self-improvement, it has become the most influential in the medical industry "cloud" platform. According to communication and display in the exhibition, it provides widely, convenient and high quality business service for the majority of exhibitors and professional audience. SNIBE has displayed all series of products, among which, Maglumi series and IBE 6000 in the exhibition. During CMEF, as an outstanding representative of the IVD industry, SNIBE presented advanced technologies of over 18 years’ experience in Chemiluminescence Immunoassay (CLIA) system. All of these products attracted numerous medical professionals. SNIBE has been dedicated to R&D in the field of CLIA all the time and is constantly expanding the market, looking forward to becoming the major supplier of CLIA solution in the world step by step.

Snibe to attend 2013 EUROMEDLAB MILANO

10 Apr 2013
Exhibition Name: 2013 EUROMEDLAB MILANO Exhibition Location: Milano, Italy Milano Convention Centre Exhibition Date: May 19-May 23 2013 Booth No: 93 Hope to meet you there!

Congratulations on successfully participated in 2013 Arab Health

27 Feb 2013
Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE Co., Ltd.) has successfully participated in Arab Health 2013 from 28th to 31st, December in Dubai, UAE. As leading CLIA provider, SNIBE has always been devoting herself to human health and keeping improving the quality to provide the best service for all worldwide partners. SNIBE presented new products, Maglumi 600 (180 T/H, compact design) and Maglumi 1000 with new design (120 T/H) during Arab Health. These two new products will further enlarge the products portfolio og Maglumi series and offer more options to clinical laboratories, health care centers, hospitals, etc. SNIBE honored the distributors in Egypt in recognition of his outstanding performance in 2012.

Snibe to attend 2013 CMEF (Shenzhen)

23 Feb 2013
Exhibition Name: 2013 CHINA MEDICAL EQUIPMENT FAIR Exhibition Location: Shenzhen International Convention & Exhibition Center Exhibition Date: Apr 17-Apr 20 2013 Booth No: H2-C20 Hope to meet you there!

Snibe Participated in MEDICA 2012 in Dusseldorf, Germany

22 Jan 2013
Shenzhen New Industries Biomedical Engineering (Snibe), the most professional supplier of Chemiluminescence Immunoassay (CLIA) system in China, has participated in MEDICA 2012 from 14th to 17th in November in Dusseldorf, Germany. Snibe presented new products, Maglumi 600 (180 tests/hour, compact design) and Maglumi 4000 (280 tests/hour) during MEDICA. These 2 new models will further enlarge the products portfolio of Maglumi series and offer more options to clinic laboratories, health care centres, hospitals and etc. Snibe honored the distributors in Spain, Italy, Tunisia and Nepal in recognition of their outstanding performance in 2012.

Snibe to attend 2013 Arab Health (Dubai)

22 Jan 2013
Exhibition Name: 2013 Arab Health Exhibition Location: Dubai International Convention & Exhibition Centre ,UAE Exhibition Date: Jan 28-31 2013 Booth Number: RK39 Hope to meet you there!

Snibe attend 2012 AACC in Los Angeles, USA

22 Jan 2013
AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and related disciplines. AACC annual meeting is the world's largest lab medicine conference with nearly 20,000 participants from more than 100 countries. 2012 AACC annual Meeting & exhibition is held from 17th -19th July. 2012 in Los Angeles, USA. As a major IVD product Supplier, Snibe attended AACC with our advanced chemiluminescence Immunoassay (CLIA) product lines. Snibe always dedicate ourselves to extending influence in the global market and become a major CLIA leader in the world.

Snibe to attend 2013 Clinical Lab Expo (Texas)

22 Jan 2013
Exhibition Name: 2013 Clinical Lab Expo Exhibition Location: George R. Brown Convention Center, Houston, Texas Exhibition Date: Jul 30-Aug 01 2013 Booth No: 4263 Hope to meet you there!
Close

About Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Sales: US$5 Million - US$99 Million
Number of Employees: 400-999
Year of Establishment: 1995
Export Markets
Asia, Europe, Asia Pacific, Middle East, Caribbean, Africa, Central America, South America, North America
Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) is a biotechnology company specializing in clinical laboratory instruments and in vitro diagnostic reagents. The company offers a range of fully automated, integrated CLIA analyzers and matching reagent kits covering more than 100 parameters. SNIBE also supplies a full portfolio of immunology, biochemistry and electrolyte products covering the major needs of hospitals, in-house and external clinical laboratories, and diagnostic centers of all sizes.
ISO 13845
ISO 9001
TUV
Close

Events Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Snibe attends JNBC 2016 as Diamond Sponsor in Tunisia

Tunisia

Snibe attends JNBC 2016 as Diamond Sponsor in Tunisia

May 17 - 20, 2016
As a diamond sponsor, Snibe attends JNBC 2016 ( Journées
Nationales de Biologie Clinique ) held by STBC ( La Société Tunisienne de
Biologie Clinique ) at l’Hôtel LE ROYAL à Yasmine Hammamet, Tunisie.
JNBC lasts three days from 12th to 14th May 2016, and you are warmly welcome
to visit us at stand 1.2 and 3.
STBC is the most professional lab exposition in Tunisia. Laboratories,
public or private, big and small, attends this exhibition from all over Tunisia.
Among them, 60% are technicians, 30% are biologists.
Snibe exhibits the innovative chemiluminescence immunoassay (CLIA) System
Maglumi 600 and Maglumi 1000 toghther with local partner Delta Distribution at
a 118 ㎡ well-drcorated eye-catching diamond booth. With the latest
technology in immunoassay, 6 models of the instruments meet different requirements
of the end users and more than 120 parameters are available.
Supported by the local partner, Snibe Chemiluminescence Immunoassay (CLIA)
System has already served many customers with good quality in Tunisia.
Focused on IVD market for more than 20 years, Snibe believe Maglumi
immunoassay system will give much more support to the public healthcare in the
future.
Snibe, Chemiluminescence Immunoassay Focused Manufacturer in Shenzhen,
China.
Tunisia
Stand #: 1,2,3

Exhibition Invitation Medlab Asia Pacific 2015

Marina Bay Sands , Singapore

Exhibition Invitation Medlab Asia Pacific 2015

March 18 - 20, 2015
Medlab Asia Pacific 2015
Marina Bay Sands , Singapore
Stand #: B10

Exhibition Invitation:JIB 2014

October 08 - 10, 2014
Important exhibition in European
CNIT - Congress & Exhibition Centre - Paris La Défense, France
Stand #: D13
Contacts: E-mail Website

Exhibition Invitation: Medic East Africa / MEDLAB East Africa, 2014

Visa Oshwal Convention Center, Nairobi, Kenya

Exhibition Invitation: Medic East Africa / MEDLAB East Africa, 2014

September 23 - 25, 2014
Date: 23 - 25 September, 2014

City: Nairobi, Kenya

Location: Visa Oshwal Convention Center

Booth No: 2D20

Welcome to visit us!
Visa Oshwal Convention Center, Nairobi, Kenya
Stand #: 2D20
FaceBook Twitter Google+ Linked in
Prenatal Screening Risk Calculation Software

Prenatal Screening Risk Calculation Software

Model: Preaccu
Request Information

Description:

The Preaccu prenatal screening risk calculation software is suitable for prenatal screening of Trisomy 21 (Down syndrome), Trisomy 18/13 (Edwards syndrome, Patau syndrome) and neural-tube defects (NTD).

Features Specifications

Features

The prenatal screening software is suitable for prenatal screening of Trisomy 21 (Down syndrome), Trisomy 18/13 (Edwards syndrome, Patau syndrome) and neural-tube defects (NTD). Request Information

Specifications

Multi-function module
● Risk calculation module
● Truncate value, reference range setting module
●Case data query, export module
●Screening conclusions personalization module
●Report set up module
●Permission control module

Support a variety of screening indicators
●free-β-HCG
●PAPP-A
●AFP
●HCG
●free Estriol (uE3)
●NT Request Information

Send A Message To This Supplier

* Required Information
* Email
To
Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) (Prenatal Screening Risk Calculation Software)
* Message

Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions